KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Total Current Liabilities: 2009-2025

Historic Total Current Liabilities for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $837.2 million.

  • Halozyme Therapeutics' Total Current Liabilities rose 669.40% to $837.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $837.2 million, marking a year-over-year increase of 669.40%. This contributed to the annual value of $139.1 million for FY2024, which is 23.65% up from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' Total Current Liabilities is $837.2 million, which was up 523.48% from $134.3 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Total Current Liabilities peaked at $837.2 million during Q3 2025, and registered a low of $91.9 million during Q1 2023.
  • Moreover, its 3-year median value for Total Current Liabilities was $131.6 million (2024), whereas its average is $188.3 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first tumbled by 72.20% in 2021, then surged by 669.40% in 2025.
  • Halozyme Therapeutics' Total Current Liabilities (Quarterly) stood at $117.1 million in 2021, then grew by 11.65% to $130.8 million in 2022, then declined by 13.99% to $112.5 million in 2023, then climbed by 23.65% to $139.1 million in 2024, then skyrocketed by 669.40% to $837.2 million in 2025.
  • Its last three reported values are $837.2 million in Q3 2025, $134.3 million for Q2 2025, and $150.4 million during Q1 2025.